December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults ...

BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...

Boston Omaha Corporation (NYSE: BOC) (the "Company", "we", or "our") announced its financial results for the fiscal year ended December 31, 2024, in connection with filing its Annual Report on Form 10 ...

The AICPA Accounting and Review Services Committee approved an update to SSARS No. 21, clarifying that practitioners are not ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

Full Year 2024 Financial Results Revenue from Continuing Operations was $20.2 million for 2024, an increase of 181% compared to $7.2 million in 2023.